The stock decreased 0.98% or $0.0791 during the last trading session, reaching $7.9909. About 4,605 shares traded. Aberdeen Indonesia Fund, Inc. (IF) has risen 29.63% since February 20, 2017 and is uptrending. It has outperformed by 12.93% the S&P500.
The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is a huge mover today! The stock decreased 17.56% or $5.931 during the last trading session, reaching $27.839. About 2.22M shares traded or 141.37% up from the average. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has declined 0.40% since February 20, 2017 and is downtrending. It has underperformed by 17.10% the S&P500.The move comes after 7 months negative chart setup for the $728.44M company. It was reported on Feb, 20 by Barchart.com. We have $25.89 PT which if reached, will make NASDAQ:ADMS worth $50.99 million less.
Analysts await Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report earnings on February, 27. They expect $-1.15 EPS, down 69.12% or $0.47 from last year’s $-0.68 per share. After $-1.04 actual EPS reported by Adamas Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 10.58% negative EPS growth.
Among 11 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 10 have Buy rating, 1 Sell and 0 Hold. Therefore 91% are positive. Adamas Pharmaceuticals has $85 highest and $16 lowest target. $48.80’s average target is 75.29% above currents $27.839 stock price. Adamas Pharmaceuticals had 28 analyst reports since August 7, 2015 according to SRatingsIntel. Zacks downgraded the stock to “Buy” rating in Friday, August 7 report. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has “Buy” rating given on Tuesday, August 8 by Piper Jaffray. On Wednesday, August 9 the stock rating was maintained by Noble Financial with “Buy”. The stock has “Buy” rating by Noble Financial on Wednesday, November 8. Mizuho maintained the shares of ADMS in report on Thursday, April 28 with “Neutral” rating. Mizuho maintained the stock with “Buy” rating in Tuesday, June 6 report. The firm earned “Buy” rating on Friday, September 15 by Needham. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has “Neutral” rating given on Thursday, May 12 by Mizuho. Piper Jaffray maintained it with “Buy” rating and $55.0 target in Tuesday, January 30 report. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) earned “Buy” rating by Mizuho on Friday, November 3.
Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company has market cap of $728.44 million. The companyÂ’s product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with ParkinsonÂ’s disease. It currently has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe AlzheimerÂ’s disease.